Skip to main content

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population-based study

Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, Juurlink DN. BMJ. 2014; 349:g6196. Epub 2014 Oct 30.


Objective — To determine whether the prescription of co-trimoxazole with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker is associated with sudden death.

Design — Population-based, nested case-control study.

Setting — Ontario, Canada, from April 1, 1994 to January 1, 2012.

Participants — Ontario residents aged 66 years or older treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Within this group, cases were those who died of sudden death shortly after receiving an outpatient prescription for one of co-trimoxazole, amoxicillin, ciprofloxacin, norfloxacin or nitrofurantoin, antibiotics often prescribed for urinary tract infections. Each case was matched with up to 4 controls on age, sex, chronic kidney disease and diabetes.

Main Outcome Measure — Odds ratio for the association between sudden death and exposure to each antibiotic relative to amoxicillin, after adjustment for predictors of sudden death using a disease risk index.

Results — Of 39,879 patients who experienced sudden death, 1,027 occurred within 7 days of antibiotic exposure and were matched to 3,733 controls. Relative to amoxicillin, co-trimoxazole was associated with an increased risk of sudden death (adjusted odds ratio 1.38; 95% confidence interval 1.09 to 1.76). The risk was marginally higher at 14 days (adjusted odds ratio 1.54; 95% confidence interval 1.29 to 1.84). This corresponds to approximately 3 sudden deaths per 1,000 co-trimoxazole prescriptions. Ciprofloxacin (a known cause of QT interval prolongation) was 3 also associated with an increased risk of sudden death (adjusted odds ratio 1.29; 95% confidence interval 1.03 to 1.62), but no such risk was observed with nitrofurantoin or norfloxacin.

Conclusions — In older patients receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, co-trimoxazole is associated with an increased risk of sudden death. The researchers speculate that unrecognized severe hyperkalemia underlies this finding. When appropriate, alternative antibiotics should be considered in such patients

View full text

Keywords: Drug interactions Drugs (antibiotics) Drugs (cardiovascular)

×